With this development, the company has now signed a total of 40 agreements in the anti-cancer segment globally, marking a significant milestone in its growing international oncology business, the company, which specialises in oncology, antibiotics and general formulations, said in a statement.
The agreement further strengthens Sakar’s presence across the emerging markets and reflects the company’s continued focus on expanding its global oncology platform.
Commenting on the development, Sanjay Shah, Managing Director, Sakar Healthcare Ltd, said: “We are encouraged by the progress in our regulatory approvals and API pipeline, supported by multiple approvals and a strong set of applications under review. This strengthens our ability to scale operations, enhance market share, and deliver meaningful revenue growth in the coming years.”
The company continues to expand its execution capabilities in highly regulated markets through consistent progress in regulatory filings and approvals, it said further.
The company has submitted 33 site variations across key partners, including Accord Healthcare Limited in the UK, Heumann Pharma GmbH & Co. Generica KG in Germany, Torrent Pharma in the UK and Tillomed Laboratories in the UK.
